Toll Free : +1-855-465-4651 | (DE) : +49 322 210 92714 | (USA) : +1-386-310-3803 | Contact : sales@qygroup.biz

Search Market Research Reports from Top Publishers

Global Overactive Bladder Treatment Drug Market Professional Survey Report By Manufacturers, Key Regions, Product and Application 2018 - 2025

Oct-2018 | Published By : QYResearch | Category : Pharmaceuticals | Pages : 90

Request for a SAMPLE REPORT

Fill up your details below and get the sample report for FREE

Global Overactive Bladder Treatment Drug Market Professional Survey Report By Manufacturers, Key Regions, Product and Application 2018 - 2025

Oct-2018 | Published By : QYResearch | Category : Pharmaceuticals | Pages : 90 | Format : PDF

In 2017, the global Overactive Bladder Treatment Drug market size was  million US$ and it is expected to reach  million US$ by the end of 2025, with a CAGR of  during 2018-2025.

This report focuses on the global Overactive Bladder Treatment Drug status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Overactive Bladder Treatment Drug development in United States, Europe and China.

The key players covered in this study
    Astellas Pharma, Inc. (Japan)
    Pfizer, Inc. (U.S.)
    Teva Pharmaceutical Industries Limited (Israel)
    Allergan, Plc (Ireland)
    Medtronic plc (Ireland)
    Mylan N.V. (U.S.)
    Endo International plc (Ireland)
    Hisamitsu Pharmaceutical Co., Inc. (Japan)
    Sanofi (France)
    Apotex, Inc. (Canada)
    Cogentix Medical, Inc. (U.S.)
    Aurobindo Pharma Limited (India)

Market segment by Type, the product can be split into
    Anticholinergics
    Solifenacin
    Oxybutynin
    Darifenacin
    Fesoterodine
    Tolterodine
    Trospium
    Others

Market segment by Application, split into
    Idiopathic Bladder Overactivity
    Neurogenic Bladder Overactivity

Market segment by Regions/Countries, this report covers
    United States
    Europe
    China
    Japan
    Southeast Asia
    India
    Central & South America

The study objectives of this report are:
    To analyze global Overactive Bladder Treatment Drug status, future forecast, growth opportunity, key market and key players.
    To present the Overactive Bladder Treatment Drug development in United States, Europe and China.
    To strategically profile the key players and comprehensively analyze their development plan and strategies.
    To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Overactive Bladder Treatment Drug are as follows:
    History Year: 2013-2017
    Base Year: 2017
    Estimated Year: 2018
    Forecast Year 2018 to 2025
For the data information by region, company, type and application, 2017 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
<pre>Table of Contents 1 Report Overview 1.1 Study Scope 1.2 Key Market Segments 1.3 Players Covered 1.4 Market Analysis by Type 1.4.1 Global Overactive Bladder Treatment Drug Market Size Growth Rate by Type (2013-2025) 1.4.2 Anticholinergics 1.4.3 Solifenacin 1.4.4 Oxybutynin 1.4.5 Darifenacin 1.4.6 Fesoterodine 1.4.7 Tolterodine 1.4.8 Trospium 1.4.9 Others 1.5 Market by Application 1.5.1 Global Overactive Bladder Treatment Drug Market Share by Application (2013-2025) 1.5.2 Idiopathic Bladder Overactivity 1.5.3 Neurogenic Bladder Overactivity 1.6 Study Objectives 1.7 Years Considered 2 Global Growth Trends 2.1 Overactive Bladder Treatment Drug Market Size 2.2 Overactive Bladder Treatment Drug Growth Trends by Regions 2.2.1 Overactive Bladder Treatment Drug Market Size by Regions (2013-2025) 2.2.2 Overactive Bladder Treatment Drug Market Share by Regions (2013-2018) 2.3 Industry Trends 2.3.1 Market Top Trends 2.3.2 Market Drivers 2.3.3 Market Opportunities 3 Market Share by Key Players 3.1 Overactive Bladder Treatment Drug Market Size by Manufacturers 3.1.1 Global Overactive Bladder Treatment Drug Revenue by Manufacturers (2013-2018) 3.1.2 Global Overactive Bladder Treatment Drug Revenue Market Share by Manufacturers (2013-2018) 3.1.3 Global Overactive Bladder Treatment Drug Market Concentration Ratio (CR5 and HHI) 3.2 Overactive Bladder Treatment Drug Key Players Head office and Area Served 3.3 Key Players Overactive Bladder Treatment Drug Product/Solution/Service 3.4 Date of Enter into Overactive Bladder Treatment Drug Market 3.5 Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type and Application 4.1 Global Overactive Bladder Treatment Drug Market Size by Type (2013-2018) 4.2 Global Overactive Bladder Treatment Drug Market Size by Application (2013-2018) 5 United States 5.1 United States Overactive Bladder Treatment Drug Market Size (2013-2018) 5.2 Overactive Bladder Treatment Drug Key Players in United States 5.3 United States Overactive Bladder Treatment Drug Market Size by Type 5.4 United States Overactive Bladder Treatment Drug Market Size by Application 6 Europe 6.1 Europe Overactive Bladder Treatment Drug Market Size (2013-2018) 6.2 Overactive Bladder Treatment Drug Key Players in Europe 6.3 Europe Overactive Bladder Treatment Drug Market Size by Type 6.4 Europe Overactive Bladder Treatment Drug Market Size by Application 7 China 7.1 China Overactive Bladder Treatment Drug Market Size (2013-2018) 7.2 Overactive Bladder Treatment Drug Key Players in China 7.3 China Overactive Bladder Treatment Drug Market Size by Type 7.4 China Overactive Bladder Treatment Drug Market Size by Application 8 Japan 8.1 Japan Overactive Bladder Treatment Drug Market Size (2013-2018) 8.2 Overactive Bladder Treatment Drug Key Players in Japan 8.3 Japan Overactive Bladder Treatment Drug Market Size by Type 8.4 Japan Overactive Bladder Treatment Drug Market Size by Application 9 Southeast Asia 9.1 Southeast Asia Overactive Bladder Treatment Drug Market Size (2013-2018) 9.2 Overactive Bladder Treatment Drug Key Players in Southeast Asia 9.3 Southeast Asia Overactive Bladder Treatment Drug Market Size by Type 9.4 Southeast Asia Overactive Bladder Treatment Drug Market Size by Application 10 India 10.1 India Overactive Bladder Treatment Drug Market Size (2013-2018) 10.2 Overactive Bladder Treatment Drug Key Players in India 10.3 India Overactive Bladder Treatment Drug Market Size by Type 10.4 India Overactive Bladder Treatment Drug Market Size by Application 11 Central & South America 11.1 Central & South America Overactive Bladder Treatment Drug Market Size (2013-2018) 11.2 Overactive Bladder Treatment Drug Key Players in Central & South America 11.3 Central & South America Overactive Bladder Treatment Drug Market Size by Type 11.4 Central & South America Overactive Bladder Treatment Drug Market Size by Application 12 International Players Profiles 12.1 Astellas Pharma, Inc. (Japan) 12.1.1 Astellas Pharma, Inc. (Japan) Company Details 12.1.2 Company Description and Business Overview 12.1.3 Overactive Bladder Treatment Drug Introduction 12.1.4 Astellas Pharma, Inc. (Japan) Revenue in Overactive Bladder Treatment Drug Business (2013-2018) 12.1.5 Astellas Pharma, Inc. (Japan) Recent Development 12.2 Pfizer, Inc. (U.S.) 12.2.1 Pfizer, Inc. (U.S.) Company Details 12.2.2 Company Description and Business Overview 12.2.3 Overactive Bladder Treatment Drug Introduction 12.2.4 Pfizer, Inc. (U.S.) Revenue in Overactive Bladder Treatment Drug Business (2013-2018) 12.2.5 Pfizer, Inc. (U.S.) Recent Development 12.3 Teva Pharmaceutical Industries Limited (Israel) 12.3.1 Teva Pharmaceutical Industries Limited (Israel) Company Details 12.3.2 Company Description and Business Overview 12.3.3 Overactive Bladder Treatment Drug Introduction 12.3.4 Teva Pharmaceutical Industries Limited (Israel) Revenue in Overactive Bladder Treatment Drug Business (2013-2018) 12.3.5 Teva Pharmaceutical Industries Limited (Israel) Recent Development 12.4 Allergan, Plc (Ireland) 12.4.1 Allergan, Plc (Ireland) Company Details 12.4.2 Company Description and Business Overview 12.4.3 Overactive Bladder Treatment Drug Introduction 12.4.4 Allergan, Plc (Ireland) Revenue in Overactive Bladder Treatment Drug Business (2013-2018) 12.4.5 Allergan, Plc (Ireland) Recent Development 12.5 Medtronic plc (Ireland) 12.5.1 Medtronic plc (Ireland) Company Details 12.5.2 Company Description and Business Overview 12.5.3 Overactive Bladder Treatment Drug Introduction 12.5.4 Medtronic plc (Ireland) Revenue in Overactive Bladder Treatment Drug Business (2013-2018) 12.5.5 Medtronic plc (Ireland) Recent Development 12.6 Mylan N.V. (U.S.) 12.6.1 Mylan N.V. (U.S.) Company Details 12.6.2 Company Description and Business Overview 12.6.3 Overactive Bladder Treatment Drug Introduction 12.6.4 Mylan N.V. (U.S.) Revenue in Overactive Bladder Treatment Drug Business (2013-2018) 12.6.5 Mylan N.V. (U.S.) Recent Development 12.7 Endo International plc (Ireland) 12.7.1 Endo International plc (Ireland) Company Details 12.7.2 Company Description and Business Overview 12.7.3 Overactive Bladder Treatment Drug Introduction 12.7.4 Endo International plc (Ireland) Revenue in Overactive Bladder Treatment Drug Business (2013-2018) 12.7.5 Endo International plc (Ireland) Recent Development 12.8 Hisamitsu Pharmaceutical Co., Inc. (Japan) 12.8.1 Hisamitsu Pharmaceutical Co., Inc. (Japan) Company Details 12.8.2 Company Description and Business Overview 12.8.3 Overactive Bladder Treatment Drug Introduction 12.8.4 Hisamitsu Pharmaceutical Co., Inc. (Japan) Revenue in Overactive Bladder Treatment Drug Business (2013-2018) 12.8.5 Hisamitsu Pharmaceutical Co., Inc. (Japan) Recent Development 12.9 Sanofi (France) 12.9.1 Sanofi (France) Company Details 12.9.2 Company Description and Business Overview 12.9.3 Overactive Bladder Treatment Drug Introduction 12.9.4 Sanofi (France) Revenue in Overactive Bladder Treatment Drug Business (2013-2018) 12.9.5 Sanofi (France) Recent Development 12.10 Apotex, Inc. (Canada) 12.10.1 Apotex, Inc. (Canada) Company Details 12.10.2 Company Description and Business Overview 12.10.3 Overactive Bladder Treatment Drug Introduction 12.10.4 Apotex, Inc. (Canada) Revenue in Overactive Bladder Treatment Drug Business (2013-2018) 12.10.5 Apotex, Inc. (Canada) Recent Development 12.11 Cogentix Medical, Inc. (U.S.) 12.12 Aurobindo Pharma Limited (India) 13 Market Forecast 2018-2025 13.1 Market Size Forecast by Regions 13.2 United States 13.3 Europe 13.4 China 13.5 Japan 13.6 Southeast Asia 13.7 India 13.8 Central & South America 13.9 Market Size Forecast by Product (2018-2025) 13.10 Market Size Forecast by Application (2018-2025) 14 Analyst's Viewpoints/Conclusions 15 Appendix 15.1 Research Methodology 15.1.1 Methodology/Research Approach 15.1.1.1 Research Programs/Design 15.1.1.2 Market Size Estimation 12.1.1.3 Market Breakdown and Data Triangulation 15.1.2 Data Source 15.1.2.1 Secondary Sources 15.1.2.2 Primary Sources 15.2 Disclaimer 15.3 Author Details</pre>


 Latest Research Reports